Table 1.
Changes in the examined variables after 3 and 6 months of canagliflozin treatment
| Pretreatment | 3 months | 6 months | |
|---|---|---|---|
| AST (IU L−1) | 45.5 ± 30.4 | 29.9 ± 15.6* | 28.6 ± 15.8* |
| ALT (IU L−1) | 74.2 ± 68.5 | 42.0 ± 31.7* | 40.4 ± 37.3* |
| γ‐GTP (IU L−1) | 80.6 ± 78.2 | 57.5 ± 54.9* | 56.2 ± 52.6* |
| LDL‐C (mg dL−1) | 126.3 ± 37.4 | 119.9 ± 32.3 | 120.3 ± 31.1 |
| HDL‐C (mg dL−1) | 53.0 ± 18.6 | 53.8 ± 17.9 | 54.5 ± 19.7 |
| TG (mg dL−1) | 225.1 ± 166.1 | 172.1 ± 103.3* | 180.7 ± 95.3* |
| UA (mg dL−1) | 5.67 ± 1.50 | 5.02 ± 1.15* | 5.11 ± 1.13* |
| BS (mg dL−1) | 138.2 ± 51.5 | 134.5 ± 52.7 | 112.9 ± 39.5* |
| HbA1C (%) | 7.45 ± 2.16 | 6.58 ± 1.25* | 6.36 ± 1.10* |
| Body weight (kg) | 73.3 ± 16.3 | 70.4 ± 16.7* | 69.6 ± 16.8* |
| Ferritin (ng mL−1) | 184.9 ± 149.1 | 143.8 ± 134.9* | 117.3 ± 107.7* |
| FIB‐4 index | 1.42 ± 0.76 | 1.31 ± 0.67 | 1.23 ± 0.63* |
Data are presented as mean ± standard deviation.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ‐GTP, gamma‐glutamyl transferase; LDL‐C, low‐density lipoprotein cholesterol; HDL‐C, high‐density lipoprotein cholesterol; TG, triglycerides; UA, uric acid; BS, blood sugar; HbA1C, glycated haemoglobin; FIB‐4, fibrosis‐4.
*
p < 0.05 vs. before treatment.